Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID: 13726583. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Sclerosis, Clinical ehyllengren@atarabio.com Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Moffitt Cancer Center Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. 2022-04-04 TOKYO, April 4, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. Media Allogeneic T-cell therapies can be readily available for rapid delivery within days. Sign up today for your free Reader Account. The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. FUJIFILM Holdings America Corporation. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . Atara will retain its expertise, staff, and capabilities in manufacturing process science to continue to innovate in initial manufacturing and scale up for allogeneic cell therapies. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. This partnership and acquisition was first announced in January 2022. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. Eric Hyllengren For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. INVESTORS & MEDIA: Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more. Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID: 13726583. January 26, 2022 16:43 ET Its lead product includes Tab-cel (tabelecleucel), a T-cell . The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. April 28, 2023. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. For more information, go to: www.fujifilmdiosynth.com. Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. Cookies are important to the proper functioning of a site. College Station, TX 77845 Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. 805-456-4772 3400 Hillerd The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Studies, Expanded Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Media These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Alex Chapman An archived replay will be available on the Company's website for 30 days. reserved. FUJIFILM Corporation has invested over USD 5.5 billion to grow the Bio CDMO business unit in order to provide our customers with long-term support across a full-range of modalities, and manufacturing scales, said Takatoshi Ishikawa, senior executive vice president, general manager Bio CDMO Division, FUJIFILM Corporation. HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT . Atara expects to report cash, cash equivalents and short-term investments of $371.1 million as of December 31, 2021. Investors Atara believes that its cash as of December 31, 2021, together with the anticipated $100.0 million payable to Atara upon closing of the strategic transaction with FDB, will be sufficient to fund . FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Atara is an allogeneic T-cell immunotherapy company. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. . Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. The Engineering MSAT team supports the technical activities associated with T-cell manufacturing across the Atara manufacturing network. Potential application for a wide range of disease-causing viral and non-viral targets. The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. Strength, Multiple 914-789-8523, Photofinishing & Personalized Photo Products. ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. The 90,000 sq. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Through this acquisition by FUJIFILM Corporation, FUJIFILM Diosynth Biotechnologies will solidify its leadership position as a complete solutions-manufacturing provider for advanced therapies. or visit our investor hub for more information. Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. Efficient, robust process with the ability to produce over a thousand doses from one healthy donor. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) . We are incredibly proud of our world-class ATOM staff and the facility and believe that this strategic partnership will meet our long-term manufacturing needs. Accordingly, we will further focus capital resources on the development and commercialization of our pipeline of potentially transformative therapeutics for serious diseases.. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. 2023 Atara Biotherapeutics, Inc. All rights QIMR Berghofer In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna. . FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. With the addition of the dedicated site in California, Fujifilm continues to build for the future to meet the growing need of advanced therapies globally., We are excited to welcome 134 new team members to the FUJIFILM Diosynth Biotechnologies family today with the acquisition of the dedicated cell therapy manufacturing facility. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a wide range of non-EBV-associated diseases. Fujifilm Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. All rights reserved. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. 2023 Atara Biotherapeutics, Inc. All rights reserved. Healthcare Providers, https://www.businesswire.com/news/home/20220401005459/en/. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). +1 979 431 3500, Biotek All 1 FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Healthcare Providers, https://www.businesswire.com/news/home/20220126006000/en/. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. achapman@atarabio.com, Atara FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies.